Pharmacotherapy of hypertension in patients with diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 11, 2001, Pages 1805-1816

  Fu, Y ^a   Deedwania, P C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

adrenergic antagonists; blockers; Angiotensin converting enzyme inhibitor; Angiotensin II receptor blockers; Calcium channel blockers; Combination therapy and review; Diabetes mellitus; Hypertension; Thiazide diuretics

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE PLUS FELODIPINE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FELODIPINE; FOSINOPRIL; GLUCOSE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; IRBESARTAN; LIPID; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ANGIONEUROTIC EDEMA; ANKLE EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COUGHING; DATA BASE; DIABETES MELLITUS; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; FLUSHING; GLUCOSE INTOLERANCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MEDICAL PARAMETERS; MORBIDITY; MORTALITY; NEPHRITIS; NEUTROPENIA; PROTEINURIA; RASH; REVIEW; RISK ASSESSMENT; THERAPY; TREATMENT PLANNING;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION;

EID: 0035170427     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.11.1805     Document Type: Review

References (88)

1. How to improve the cardiac prognosis for diabetes
2. The cardiovascular dysmetabolic syndrome
3. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. (UKPDS 38)
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33)
5. Efficacy of atenolol and captopril in reducing risk of both macrovascular and microvascular complications in Type 2 diabetes (UKPDS 39)
6. Epidemiology of Type 2 diabetes: Risk factors
7. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V
8. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting Type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications
9. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-91
10. Risk factors for coronary heart disease mortality among persons with diabetes
11. Epidemiology of atherosclerosis: An updated overview
12. An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Framingham Heart Study
13. Systolic Hypertension in Europe Trial Investigators: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
14. End-stage renal failure in Type 2 diabetes: A medical catastrophe of worldwide dimensions
15. Cost effectiveness of intensive treatment of hypertension
16. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with Type 2 diabetes: (UKPDS 40)
17. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients
18. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
19. Prevalence, awareness, treatment and control of hypertension in the elderly: Results from a population survey
20. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study
21. Standard of medical care for patients with diabetes mellitus
22. 1999 Canadian recommendations for the management of hypertension
23. Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting-Enzyme Inhibitor in Normotensive and Hypertensive Subjects
24. Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 2: Beta-blockers
25. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
26. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
27. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS)
28. ACE inhibitor-induced hypoglycaemia
29. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
30. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?
31. Drug Therapy: Angiotensin receptors and their antagonists
32. Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 3: Angiotensin-converting-enzyme, ACE inhibitors
33. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema
34. Angiotensin II receptor Blockers
35. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
36. Overview of the angiotensin-converting-enzyme inhibitors
37. Mechanism of antihypertensive effect of thiazide diuretics
38. Pathogenesis and treatment of hypertension associated with diabetes mellitus
39. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
40. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP)
41. Excess mortality associated with diuretic therapy in diabetes mellitus
42. Diuretic therapy for hypertension and the risk of primary cardiac arrest
43. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients
44. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. For the atherosclerosis risk in communities study
45. Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance
46. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with Type 2 diabetes mellitus. A randomised, controlled trial
47. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia
48. Beta-adrenoceptor blockade and hypoglycaema
49. Higher glycaemic thresholds for symptoms during beta-adrenergic blockade in IDDM
50. The effect of sustained release verapamil on glucose metabolism in patients with NIDDM
51. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
52. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension
53. Outcome results of the fosinopril versus amlodipine cardiovascular events randomised trial (FACET) in patients with hypertension and NIDDM
54. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium systemic hypertension
55. Hyperinsulinemia, insulin resistance, and the treatment of hypertension
56. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-age men
57. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Major cardiovascular events in hypertensive patients randomised to doxazosin vs. chlorthalidone
58. Effects of prazosin therapy on blood pressure, renal function, and body fluid composition
59. Vasodilators and regression of left ventricular hypertrophy: Hydralazine versus prazosin in hypertensive patients
60. Comparison of 5 antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study
61. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: Comparison of six antihypertensive agents
62. The chymase-angiotensin system in humans: Biochemistry, molecular biology and potential role in cardiovascular diseases
63. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
64. Long-term comparison of losartan and enalapril on kidney function in hypertensive Type 2 diabetics with early nephropathy
65. Safety and efficacy of irbesartan in hypertensive patients with Type 2 diabetes and proteinuria
66. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes
67. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2
68. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study
69. For the Nordil Study Group: Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
70. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
71. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
72. Use of enalapril to attenuate decline in renal function in normotensive, normo-albuminuric patients with Type 2 diabetes mellitus. A randomised, controlled trial
73. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive Type II diabetic patients
74. Renoprotective role of ACE inhibitors in diabetic nephropathy
75. Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study
76. Achievement and safety of low blood pressure goal in chronic renal disease: The Modification of Diet in Renal Disease Study Group
77. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: Results of a placebo-controlled randomised trial
78. Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension
79. Management of hypertension: The role of combination therapy
80. Treating hypertension in non-insulin-dependent diabetes: A comparison of atenolol, nifedipine, and captopril combined with bendrofluazide
81. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with Type II diabetes
82. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
83. Captopril + hydrochlorothiazide versus captopril + nifedipine in the treatment of arterial hypertension in diabetes mellitus Type II
84. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive Type 2 diabetes
85. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients
86. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial
87. Heart disease in patients with diabetes mellitus